<Version>
  <xmlSource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlSource>
  <Section SecID="390" OrdBy="100" Name="General">
    <Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;AASLD guidelines for treatment of chronic hepatitis B.&lt;/div&gt;" />
    </Field>
    <Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016 Jan;63(1):261-83. [132 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26566064&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
    <Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of this guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This updates a previous version: Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009 Sep;50(3):661-2. [304 references]&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline meets NGC's 2013 (revised) inclusion criteria.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="420" OrdBy="300" Name="Recommendations">
    <Field FieldID="151" OrdBy="310" ID="421" Name="Major Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Recommendations are followed by quality of evidence ratings (&lt;strong&gt;High&lt;/strong&gt;, &lt;strong&gt;Moderate&lt;/strong&gt;, &lt;strong&gt;Low&lt;/strong&gt;, and &lt;strong&gt;Very Low&lt;/strong&gt;), and the strength of the recommendations (&lt;strong&gt;Strong&lt;/strong&gt; or &lt;strong&gt;Conditional&lt;/strong&gt;) which are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Note from the National Guideline Clearinghouse (NGC)&lt;/strong&gt;: Technical remarks designed to facilitate implementation accompany each recommendation and can be found in the original guideline document.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Treatment of Persons with Immune-Active Chronic Hepatitis B (CHB)&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The American Association for the Study of Liver Diseases (AASLD) recommends antiviral therapy for adults with immune-active CHB (hepatitis B e antigen [HBeAg] negative or HBeAg positive) to decrease the risk of liver-related complications. (&lt;strong&gt;Quality/Certainty of Evidence: Moderate, Strength of Recommendation: Strong&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The AASLD recommends pegylated interferon (Peg-IFN), entecavir, or tenofovir as preferred initial therapy for adults with immune-active CHB. (&lt;strong&gt;Quality/Certainty of Evidence: Low, Strength of Recommendation: Strong&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Treatment of Adults with Immune-Tolerant CHB&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The AASLD recommends against antiviral therapy for adults with immune-tolerant CHB. (&lt;strong&gt;Quality/Certainty of Evidence: Moderate, Strength of Recommendation: Strong&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The AASLD suggests that alanine aminotransferase (ALT) levels be tested at least every 6 months for adults with immune-tolerant CHB to monitor for potential transition to immune-active or -inactive CHB. (&lt;strong&gt;Quality/Certainty of Evidence: Very low, Strength of Recommendation: Conditional&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The AASLD suggests antiviral therapy in the select group of adults &amp;gt;40 years of age with normal ALT and elevated hepatitis B virus deoxyribonucleic acid (HBV DNA) (&amp;ge;1,000,000 IU/mL) and liver biopsy showing significant necroinflammation or fibrosis. (&lt;strong&gt;Quality/Certainty of Evidence: Very low, Strength of Recommendation: Conditional&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Treatment of HBeAg Positive Immune-Active Chronic Hepatitis Persons Who Seroconvert to Anti-HBe on Nucleos(t)ide Analog (NA) Therapy&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The AASLD suggests that HBeAg-positive adults without cirrhosis with CHB who seroconvert to anti-HBe on therapy discontinue NAs after a period of treatment consolidation. (&lt;strong&gt;Quality/Certainty of Evidence: Very Low, Strength of Recommendation: Conditional&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The AASLD suggests indefinite antiviral therapy for HBeAg-positive adults with cirrhosis with CHB who seroconvert to anti-HBe on NA therapy, based on concerns for potential clinical decompensation and death, unless there is a strong competing rationale for treatment discontinuation. (&lt;strong&gt;Quality/Certainty of Evidence: Very Low, Strength of Recommendation: Conditional&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Duration of Treatment in Persons with HBeAg-Negative Immune-Active CHB&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The AASLD suggests indefinite antiviral therapy for adults with HBeAg-negative immune-active CHB unless there is a competing rationale for treatment discontinuation. (&lt;strong&gt;Quality/Certainty of Evidence: Low, Strength of Recommendation: Conditional&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Renal and Bone Disease in Persons on NA Therapy&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The AASLD suggests no preference between entecavir and tenofovir regarding potential long-term risks of renal and bone complications. (&lt;strong&gt;Quality/Certainty of Evidence: Very Low (bone); Low (renal), Strength of Recommendation: Conditional&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Management of Persons with Persistent Low-Level Viremia on NA Therapy&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The AASLD suggests that persons with persistent low level viremia (&amp;lt;2,000 IU/mL) on entecavir or tenofovir monotherapy continue monotherapy, regardless of ALT. (&lt;strong&gt;Quality/Certainty of Evidence: Very Low, Strength of Recommendation: Conditional&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The AASLD suggests one of two strategies in persons with virological breakthrough on entecavir or tenofovir monotherapy: either switch to another antiviral monotherapy with high barrier to resistance or add a second antiviral drug that lacks cross-resistance. (&lt;strong&gt;Quality/Certainty of Evidence: Very Low, Strength of Recommendation: Conditional&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Management of Adults with Cirrhosis and Low-Level Viremia&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The AASLD suggests that adults with compensated cirrhosis and low levels of viremia (&amp;lt;2,000 IU/ mL) be treated with antiviral therapy to reduce the risk of decompensation, regardless of ALT level. (&lt;strong&gt;Quality/Certainty of Evidence: Very Low, Strength of Recommendation: Conditional&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The AASLD recommends that hepatitis B surface antigen (HBsAg)-positive adults with decompensated cirrhosis be treated with antiviral therapy indefinitely regardless of HBV DNA level, HBeAg status, or ALT level to decrease risk of worsening liver-related complications. (&lt;strong&gt;Quality/Certainty of Evidence: Moderate, Strength of Recommendation: Strong&lt;/strong&gt;) &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Treatment of CHB in Pregnancy&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The AASLD suggests antiviral therapy to reduce the risk of perinatal transmission of hepatitis B in HBsAg-positive pregnant women with an HBV DNA level &amp;gt;200,000 IU/mL. (&lt;strong&gt;Quality/Certainty of Evidence: Low, Strength of Recommendation: Conditional&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The AASLD recommends against the use of antiviral therapy to reduce the risk of perinatal transmission of hepatitis B in the HBsAg-positive pregnant woman with an HBV DNA &amp;le;200,000 IU/mL. (&lt;strong&gt;Quality/Certainty of Evidence: Low, Strength of Recommendation: Strong&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Treatment of CHB in Children&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The AASLD suggests antiviral therapy in HBeAg-positive children (ages 2 to &amp;lt;18 years) with both elevated ALT and measurable HBV DNA levels, with the goal of achieving sustained HBeAg seroconversion. (&lt;strong&gt;Quality/Certainty of Evidence: Moderate, Strength of Recommendation: Conditional&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The AASLD recommends against use of antiviral therapy in HBeAg-positive children (ages 2 to &amp;lt;18 years) with persistently normal ALT, regardless of HBV DNA level. (&lt;strong&gt;Quality/Certainty of Evidence: Very Low, Strength of Recommendation: Strong&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Rating the Quality of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Rating the Quality of Evidence&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Study Design&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Initial Rating of Quality of Evidence&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Rate Down When&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Rate Up When&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Randomized controlled trials (RCTs)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High&lt;br /&gt;&#xD;&#xA;            Moderate&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; rowspan=&quot;2&quot;&gt;Risk of bias&lt;br /&gt;&#xD;&#xA;            Inconsistency&lt;br /&gt;&#xD;&#xA;            Imprecision&lt;br /&gt;&#xD;&#xA;            Indirectness&lt;br /&gt;&#xD;&#xA;            Publication bias&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; rowspan=&quot;2&quot;&gt;Large effect (e.g., relative risk [RR]: 0.5)&lt;br /&gt;&#xD;&#xA;            Very large effect (e.g., RR: 0.2)&lt;br /&gt;&#xD;&#xA;            Dose response gradient&lt;br /&gt;&#xD;&#xA;            All plausible confounding would increase the association&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Observational&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Low&lt;br /&gt;&#xD;&#xA;            Very low&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Determinants of the Strength of a Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Quality of evidence &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Balance of benefits and harms &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patient values and preferences &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Resources and costs &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Implications of the Strength of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Implications of the Strength of Recommendation&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Strong&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Population: Most people in this situation would want the recommended course of action and only a small proportion would not. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Health care workers: Most people should receive the recommended course of action. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Policy makers: The recommendation can be adapted as a policy in most situations. &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Conditional&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Population: The majority of people in this situation would want the recommended course of action, but many would not. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Health care workers: Be prepared to help patients make a decision that is consistent with their values using decision aids and shared decision making. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Policy makers: There is a need for substantial debate and involvement of stakeholders. &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="138" OrdBy="330" ID="423" Name="Clinical Algorithm(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="396" OrdBy="400" Name="Scope">
    <Field FieldID="140" OrdBy="405" ID="397" Name="Disease/Condition(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Chronic hepatitis B (CHB) virus (HBV) infection&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: Management of hepatitis B in patients waiting for liver transplantation and prevention of recurrent hepatitis B post-liver transplant will not be discussed in these guidelines.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="103" OrdBy="410" ID="398" Name="Guideline Category" Type="picklist-many">
      <FieldValue Value="Management" />
      <FieldValue Value="Risk Assessment" />
      <FieldValue Value="Treatment" />
    </Field>
    <Field FieldID="113" OrdBy="415" ID="399" Name="Clinical Specialty" Type="picklist-many">
      <FieldValue Value="Family Practice" />
      <FieldValue Value="Gastroenterology" />
      <FieldValue Value="Infectious Diseases" />
      <FieldValue Value="Internal Medicine" />
      <FieldValue Value="Obstetrics and Gynecology" />
      <FieldValue Value="Pediatrics" />
    </Field>
    <Field FieldID="114" OrdBy="420" ID="400" Name="Intended Users" Type="picklist-many">
      <FieldValue Value="Advanced Practice Nurses" />
      <FieldValue Value="Health Care Providers" />
      <FieldValue Value="Nurses" />
      <FieldValue Value="Physician Assistants" />
      <FieldValue Value="Physicians" />
      <FieldValue Value="Public Health Departments" />
    </Field>
    <Field FieldID="129" OrdBy="425" ID="401" Name="Guideline Objective(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To present official recommendations of the American Association for the Study of Liver Diseases (AASLD) on the treatment of chronic hepatitis B (CHB) virus (HBV) infection in adults and children&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="132" OrdBy="430" ID="402" Name="Target Population" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Adults and children with chronic hepatitis B (CHB) virus (HBV) infection&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="133" OrdBy="435" ID="403" Name="Interventions and Practices Considered" Type="text">
      <FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Treatment of persons with immune-active chronic hepatitis B (CHB) (antiviral therapy [pegylated interferon (Peg-IFN)], entecavir, or tenofovir) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of adults with immune-tolerant CHB&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Monitoring of alanine aminotransferase (ALT) levels &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Antiviral therapy (as indicated) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment of hepatitis B e antigen (HBeAg) positive immune-active chronic hepatitis persons who seroconvert to anti-HBe on nucleos(t)ide analog (NA) therapy&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Discontinuation of NA after period of treatment consolidation &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Indefinite antiviral therapy &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Duration of treatment in persons with HBeAg-negative immune-active CHB (indefinite antiviral therapy) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of persons with persistent low-level viremia on NA therapy&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Continuation of monotherapy (entecavir or tenofovir) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Switching to another antiviral monotherapy with high barrier to resistance &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Adding a second antiviral drug that lacks cross-resistance &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of adults with cirrhosis and low-level viremia (antiviral therapy) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment of CHB in pregnancy (antiviral therapy) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment of CHB in children (antiviral therapy) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;" />
    </Field>
    <Field FieldID="134" OrdBy="440" ID="404" Name="Major Outcomes Considered" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Cirrhosis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Decompensation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hepatocellular carcinoma (HCC) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Death &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Loss of hepatitis B surface antigen (HbsAg) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reactivation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Seroreversion &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Renal function &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hypophosphatemia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Bone health &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hepatitis B virus (HBV) resistance &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Clinical flare &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Loss of hepatitis B e antigen (HBeAg) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Chronic hepatitis B (CHB) virus in the infant &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Maternal and fetal/infant safety &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
  </Section>
  <Section SecID="405" OrdBy="500" Name="Methodology">
    <Field FieldID="109" OrdBy="505" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many">
      <FieldValue Value="Hand-searches of Published Literature (Primary Sources)" />
      <FieldValue Value="Searches of Electronic Databases" />
      <FieldValue Value="Searches of Unpublished Data" />
    </Field>
    <Field FieldID="135" OrdBy="510" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A methodologist moderated and facilitated the process of question development. A separate group of American Association for the Study of Liver Diseases (AASLD) content experts collaborated with an independent research group with expertise in conducting systematic reviews to synthesize the available evidence informing the key questions. See the original guideline document for the key questions and see the &quot;Availability of Companion Documents&quot; field for the systematic reviews.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Antiviral Therapy in Chronic Hepatitis B Viral Infection during Pregnancy: A Systematic Review and Meta-analysis&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Eligibility Criteria&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The systematic review group included controlled or comparative studies that enrolled pregnant women diagnosed with chronic hepatitis B (CHB) virus (HBV) infection (characterized by the presence of hepatitis B surface antigen [HBsAg] for more than 6 months), who received antiviral therapy and reported the outcomes of interest, including prevention of mother-to-child-transmission (MTCT) of HBV, clinical efficacy, and adverse outcomes from antiviral therapy to both mothers and newborns. Both English and non-English-language studies were included. The systematic review group excluded studies that enrolled infants who did not receive immunization during the first week postpartum; studies of patients coinfected with hepatitis C, hepatitis D, or human immunodeficiency virus (HIV); patients receiving steroids, chemotherapy/immunotherapy, liver transplantation, and hemodialysis; and uncontrolled studies or studies published as abstracts only.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Search Strategy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A comprehensive search of Medline In-Process &amp;amp; Other Non-Indexed Citations, Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, and Scopus was conducted from early 1988 to September 11, 2014. The search strategy was designed and conducted by an experienced librarian with input from the principal investigator. Controlled vocabulary supplemented with keywords was used to search for studies of antivirals for hepatitis B in pregnancy. Details of the search strategy are available in Supporting Table 1 of the systematic review. A manual search of bibliographies of the included studies and relevant systematic reviews was conducted. Content experts from the American Association for the Study of Liver Diseases (AASLD) were also queried for potential references.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Study Selection&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Two independent reviewers screened titles and abstracts for potential eligibility in duplicate using an online reference management system (DistillerSR; Evidence Partners, Inc.). Included abstracts were then reviewed in full text following the same procedure. Disagreements were reconciled by consensus or by a third reviewer.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Antiviral Therapy in Management of Chronic Hepatitis B Viral Infection in Children: A Systematic Review and Meta-analysis&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Eligibility Criteria&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The systematic review group included studies that enrolled children (&amp;lt;18 years) with chronic HBV infection treated with antiviral therapy. Due to the anticipated limited number of randomized controlled trials (RCTs) evaluating patient-important (clinical) outcomes, the group included observational studies that evaluated such outcomes. Outcomes of interest were cirrhosis, decompensated liver disease, hepatocellular carcinoma (HCC), alanine aminotransferase (ALT) normalization, HBV deoxyribonucleic acid (DNA) suppression, hepatitis B e antigen/hepatitis B surface antigen (HBeAg/HBsAg) seroconversion, and HBeAg/HBsAg loss. They included both English and non-English-language studies. They excluded studies enrolling adults; patients coinfected with hepatitis C, hepatitis D, or HIV; patients receiving combination therapy, steroids, or chemotherapy/immunotherapy; liver transplant recipients; and hemodialysis patients. Supporting Table S1 of the systematic review describes the detailed inclusion and exclusion criteria.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Search Strategy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The search strategy was designed and conducted by an experienced librarian with input from the principal investigator. A comprehensive search of Medline In-Process &amp;amp; Other Non-Indexed Citations, MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Scopus was conducted from January 1988 to December 2, 2014. Controlled vocabulary supplemented with keywords was used to search for studies of antiviral therapy for hepatitis B in children. Supporting Table S2 of the systematic review provides details of the search strategy. The systematic review group conducted a manual search of bibliographies of the included studies and previous systematic reviews to identify relevant studies. Content experts from the AASLD were also queried for potential references.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Study Selections&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Using an online reference management system (DistillerSR; Evidence Partners, Inc.), two reviewers independently screened titles and abstracts. Full texts of the included abstracts were retrieved and screened in duplicate. Disagreements were harmonized by consensus or arbitration by a third reviewer. The Committee calculated interrater agreement (kappa) during the full text screening to observe the agreement between reviewers.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Antiviral Therapy for Chronic Hepatitis B Viral Infection in Adults: A Systematic Review and Meta-analysis&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Eligibility Criteria&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The systematic review group included RCTs and controlled observational studies that enrolled adults &amp;ge;18 years old diagnosed with chronic HBV infection who received antiviral therapy. They excluded studies that included patients with acute HBV infection; patients who were pregnant; patients coinfected with hepatitis C or D or HIV; patients receiving corticosteroids, chemotherapy, or immunosuppressive therapy; transplant recipients; and hemodialysis patients, as well as studies without control or comparison groups. Supporting Table S1 of the systematic review summarizes the inclusion and exclusion criteria for each key question.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Search Strategy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;An experienced Mayo Clinic librarian conducted a comprehensive search of Medline In-Process &amp;amp; Other Non-Indexed Citations, MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus from early 1988 to September 16, 2014. Controlled vocabulary supplemented with keywords was used to search for comparative studies of antivirals for CHB. No language restrictions were used. Members from the AASLD HBV guideline methodology and writing committees helped identify additional studies. Supporting Table S2 of the systematic review specifies the detailed search strategy.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Study Selections&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Two reviewers independently screened titles and abstracts for potential eligibility using an online reference management system (DistillerSR; Evidence Partners, Inc.). Full texts of the included abstracts were retrieved and screened in duplicate. Disagreements were resolved by seeking consensus or arbitration by a third reviewer. Interreviewer agreement (kappa) was calculated during each screening level to assess agreement between reviewers. For Population Intervention Comparison Outcome questions where no studies meeting the predefined criteria were found, the AASLD HBV guideline methodology committee performed manual searches for uncontrolled observational studies. Data from these studies were summarized narratively and in general consistent with low-quality evidence.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="136" OrdBy="515" ID="408" Name="Number of Source Documents" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Antiviral Therapy in Chronic Hepatitis B Viral Infection during Pregnancy: A Systematic Review and Meta-analysis&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The initial search resulted in 734 citations and three systematic reviews that included the China Biological Medicine Database and summarized additional studies published in Chinese. The committee eventually included 26 studies. The average weighted kappa for study selection was 0.82. The study selection process and reasons for exclusions are depicted in Figure 1 of the systematic review (see the &quot;Availability of Companion Documents&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Antiviral Therapy in Management of Chronic Hepatitis B Viral Infection in Children: A Systematic Review and Meta-analysis&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;From the 2321 citations identified with the primary search strategy, 14 studies that enrolled 1425 children were finally included. Two studies evaluated the clinical (patient-important) outcomes of death, cirrhosis, and HCC and 12 studies reported intermediate outcomes. Average weighted kappa (interrater agreement) for study selection was 0.75. Details of study selection and reasons for exclusion are described in Figure 1 of the systematic review (see the &quot;Availability of Companion Documents&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Antiviral Therapy for Chronic Hepatitis B Viral Infection in Adults: A Systematic Review and Meta-analysis&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A total of 73 studies were included. Figure 1 of the systematic review (see the &quot;Availability of Companion Documents&quot; field) describes the details of the selection process. The average weighted kappa for study selection was 0.78. Controlled studies that reported the outcomes of interest were only available for questions 1, 2, 3, and 5. Uncontrolled studies that are relevant to questions 4, 6, and 7 are summarized in Supporting Information. Supporting Table S4 in the systematic review provides the Grading of Recommendations Assessment, Development and Evaluation (GRADE) summary of the evidence.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="115" OrdBy="520" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice">
      <FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" />
    </Field>
    <Field FieldID="149" OrdBy="525" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Rating the Quality of Evidence&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Rating the Quality of Evidence&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Study Design&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Initial Rating of Quality of Evidence&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Rate Down When&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Rate Up When&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Randomized controlled trials (RCTs)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High&lt;br /&gt;&#xD;&#xA;            Moderate&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; rowspan=&quot;2&quot;&gt;Risk of bias&lt;br /&gt;&#xD;&#xA;            Inconsistency&lt;br /&gt;&#xD;&#xA;            Imprecision&lt;br /&gt;&#xD;&#xA;            Indirectness&lt;br /&gt;&#xD;&#xA;            Publication bias&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; rowspan=&quot;2&quot;&gt;Large effect (e.g., relative risk [RR]: 0.5)&lt;br /&gt;&#xD;&#xA;            Very large effect (e.g., RR: 0.2)&lt;br /&gt;&#xD;&#xA;            Dose response gradient&lt;br /&gt;&#xD;&#xA;            All plausible confounding would increase the association&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Observational&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Low&lt;br /&gt;&#xD;&#xA;            Very low&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="116" OrdBy="530" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many">
      <FieldValue Value="Meta-Analysis" />
      <FieldValue Value="Review of Published Meta-Analyses" />
      <FieldValue Value="Systematic Review with Evidence Tables" />
    </Field>
    <Field FieldID="150" OrdBy="535" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;See the &quot;Availability of Companion Documents&quot; field for the systematic reviews commissioned to support this guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Antiviral Therapy in Chronic Hepatitis B Viral Infection during Pregnancy: A Systematic Review and Meta-analysis&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Data Extraction&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For each study, data extraction was done in duplicate using a standardized, pretested form. A third reviewer compared data and resolved inconsistencies by referring to the full text of the articles. The systematic review group extracted the following data from each study: study characteristics, patient baseline characteristics, intervention details, and outcomes of interest.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Outcomes&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The systematic review group was interested in the following outcomes: infant outcomes including the risk of mother-to-child transmission (MTCT) transmission, defined by hepatitis B surface antigen (HBsAg) seropositivity at 6-12 months or hepatitis B virus deoxyribonucleic acid (HBV DNA) positivity at 6-12 months; Apgar score (1 minute); prematurity rate; and congenital malformation rate. Maternal outcomes included HBV DNA suppression, alanine aminotransferase (ALT) normalization, hepatitis B e antigen (HBeAg) loss, HBeAg seroconversion, cesarean section rate, postpartum hemorrhage rate, and elevated creatine kinase.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Risk of Bias Assessment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Two reviewers independently assessed the risk of bias (i.e., systematic error) using the Cochrane Risk of Bias assessment tool and the Newcastle-Ottawa Scale for randomized controlled trials (RCTs) and observational studies, respectively. The quality of evidence (i.e., certainty in the estimates) was evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Criteria used to evaluate quality of evidence were risk of bias, indirectness (surrogate outcomes), imprecision (wide confidence intervals), inconsistency (heterogeneity), and publication bias.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Statistical Analysis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For dichotomized outcomes, the systematic review group calculated the risk ratio (RR) and 95% confidence intervals (CIs) using binomial distribution. They then pooled the log-transformed RRs using the DerSimonian and Laird random-effect models and estimated heterogeneity using the Mantel-Haenszel model. For continuous outcomes, the committee calculated the weighted difference in means between the baseline and the longest duration of follow-up for each study and the pooled effect size using the DerSimonian and Laird random-effect model. To measure the overall heterogeneity across the included studies, the systematic review group used the I&lt;sup&gt;2&lt;/sup&gt; statistic, where I&lt;sup&gt;2&lt;/sup&gt; &amp;gt;50% suggests high heterogeneity. All statistical analyses were conducted using STATA, version 13 (StataCorp LP, College Station, TX). They planned to explore the impact of publication bias using the Egger regression asymmetry test and constructing funnel plots if a sufficient number of studies (&amp;gt;20) per outcome was available and heterogeneity was low.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Antiviral Therapy in Management of Chronic Hepatitis B Viral Infection in Children: A Systematic Review and Meta-analysis&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Data Extraction&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Data extraction was done in duplicate using a standardized, piloted form. A third reviewer compared the reviewers' entered data and resolved any inconsistencies by referring to the full text of the article. The systematic review group extracted the following variables from each study: study characteristics, patient baseline characteristics, intervention details, and outcomes of interest.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Risk of Bias Assessment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Two reviewers independently assessed the risk of bias (i.e., systematic error) using the Cochrane risk of bias tool and the Newcastle-Ottawa Scale for RCTs and observational studies. Quality of evidence (i.e., certainty in the estimates) was evaluated using the GRADE approach. Criteria used to evaluate quality of evidence were risk of bias, indirectness (surrogate outcomes), imprecision (wide confidence intervals), inconsistency (heterogeneity), and publication bias.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Statistical Analysis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For dichotomized outcomes, the systematic review group calculated RRs and 95% CIs using binomial distribution. They then pooled the log-transformed RRs using the DerSimonian and Laird random-effect method with the heterogeneity estimated from the Mantel-Haenszel model. To measure the overall heterogeneity across the included studies, they calculated the I&lt;sup&gt;2&lt;/sup&gt; statistic, with I&lt;sup&gt;2&lt;/sup&gt; &amp;gt;50% suggesting high heterogeneity. All statistical analyses were conducted using STATA, version 13 (StataCorp LP, College Station, TX). The systematic review group explored the impact of publication bias using the Egger regression asymmetry test and by constructing funnel plots if a sufficient number of studies (&amp;gt;20) per outcome was available and heterogeneity was low.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Antiviral Therapy for Chronic Hepatitis B Viral Infection in Adults: A Systematic Review and Meta-analysis&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Data Extraction&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Data extraction was done using a standardized, piloted form. The systematic review group extracted data on study characteristics, patient characteristics, intervention details, and outcomes of interest.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Methodological Quality and Risk of Bias Assessment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The systematic review group used the Cochrane Risk of Bias assessment tool and modified Newcastle-Ottawa Scale to assess the risk of bias in RCTs and observational studies, respectively. Quality of evidence (i.e., certainty in the estimates) was evaluated using the GRADE approach. Criteria used to evaluate quality of evidence were risk of bias, indirectness (surrogate outcomes), imprecision (wide confidence intervals), inconsistency (heterogeneity), and publication bias.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Statistical Analysis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For dichotomized outcomes, the systematic review group calculated RRs and 95% CIs using binomial distribution. They then pooled the log-transformed RRs using the DerSimonian and Laird random-effects models and estimated heterogeneity using the Mantel-Haenszel model. To measure the overall heterogeneity across the included studies, the systematic review group calculated the I&lt;sup&gt;2&lt;/sup&gt; statistic, where I&lt;sup&gt;2&lt;/sup&gt; &amp;gt;50% suggests a high degree of heterogeneity. All statistical analyses were conducted using STATA, version 13 (StataCorp LP, College Station, TX). To explore heterogeneity, they conducted subgroup analysis for studies enrolling patients with more advanced liver disease; they performed stratified analysis for the following groups: compensated cirrhosis, decompensated cirrhosis, acute on chronic liver failure, and severe acute exacerbations of chronic hepatitis B (CHB). The systematic review group explored the impact of publication bias using the Egger regression asymmetry test and constructing funnel plots if a sufficient number of studies (&amp;gt;20) per outcome was available and heterogeneity was low.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="112" OrdBy="540" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice">
      <FieldValue Value="Expert Consensus" />
    </Field>
    <Field FieldID="145" OrdBy="545" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A methodologist moderated and facilitated the process of question development. A separate group of American Association for the Study of Liver Diseases (AASLD) content experts collaborated with an independent research group with expertise in conducting systematic reviews to synthesize the available evidence informing these key questions. By multiple face-to-face meetings, phone conferences, and electronic communication, the systematic review group finalized evidence summaries following the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. In this approach, the quality of evidence (i.e., certainty in evidence) is rated as high, moderate, low, or very low based on the domains of precision, directness, consistency, and risk of bias and publication bias. The guideline-writing group based its recommendations on the quality of evidence, balance of benefits and harms, patients' values and preferences, and clinical context. Recommendations are graded as strong (apply to most patients with minimal variation) or conditional (apply to the majority of patients whose values and preferences are consistent with the course of action). Technical remarks are added to recommendations to facilitate implementation. Evidence profiles corresponding to five of the key questions are presented as an appendix to the original guideline document. For the remaining questions with sparse and indirect evidence, relevant studies are summarized after each recommendation (see the original guideline document).&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="146" OrdBy="550" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Determinants of the Strength of a Recommendation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Quality of evidence &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Balance of benefits and harms &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patient values and preferences &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Resources and costs &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Implications of the Strength of Recommendation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Implications of the Strength of Recommendation&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Strong&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Population: Most people in this situation would want the recommended course of action and only a small proportion would not. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Health care workers: Most people should receive the recommended course of action. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Policy makers: The recommendation can be adapted as a policy in most situations. &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Conditional&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Population: The majority of people in this situation would want the recommended course of action, but many would not. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Health care workers: Be prepared to help patients make a decision that is consistent with their values using decision aids and shared decision making. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Policy makers: There is a need for substantial debate and involvement of stakeholders. &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="148" OrdBy="565" ID="417" Name="Cost Analysis" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="104" OrdBy="570" ID="418" Name="Method of Guideline Validation" Type="picklist-choice">
      <FieldValue Value="Internal Peer Review" />
    </Field>
    <Field FieldID="130" OrdBy="575" ID="419" Name="Description of Method of Guideline Validation" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This Practice Guideline was approved by the American Association for the Study of Liver Diseases (AASLD) on August 1, 2015.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations">
    <Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations">
    <Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Clearance of hepatitis B surface antigen (HBsAg), whether spontaneous or after antiviral therapy, reduces risk of hepatic decompensation and improves survival. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patient selection and timing of treatment are critical decisions in order to avoid overtreatment, maximize therapeutic benefit while limiting duration of therapy, and minimize risk for antiviral drug resistance later in life. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Antiviral therapy in patients with immune active chronic hepatitis B (CHB) virus (HBV) infection can reduce the risk of cirrhosis, decompensated liver disease, and hepatocellular carcinoma. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In immune tolerant patients, moderate-quality evidence supports improved intermediate outcomes with antiviral therapy. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Antiviral therapy improves HBV suppression and reduces mother to child transmission (MTCT) in women with chronic HBV infection with high viral load compared to the use of hepatitis B immunoglobulin and vaccination alone; the use of telbivudine, lamivudine, and tenofovir appears to be safe in pregnancy with no increased adverse maternal or fetal outcome. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
    <Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Overall, all nucleos(t)ide analogs (NAs) have an excellent safety profile across a wide spectrum of persons with chronic hepatitis B (CHB), including those with decompensated cirrhosis and transplant recipients. The side effects listed below for NAs are infrequent.&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Pegylated interferon (Peg-IFN)-2a (adult): Flu-like symptoms, fatigue, mood disturbances, cytopenias, autoimmune disorders in adults, &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;IFN-&amp;alpha;-2b (children): Anorexia and weight loss &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Lamivudine: Pancreatitis, lactic acidosis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Telbivudine: Creatine kinase elevations and myopathy, peripheral neuropathy, lactic acidosis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Entecavir: Lactic acidosis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adefovir: Acute renal failure, Fanconi syndrome, nephrogenic diabetes insipidus, lactic acidosis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Tenofovir: Nephropathy, Fanconi syndrome, osteomalacia, lactic acidosis &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="430" OrdBy="800" Name="Contraindications">
    <Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;Pegylated interferon (Peg-IFN) is contraindicated in persons with autoimmune disease, uncontrolled psychiatric disease, cytopenias, severe cardiac disease, uncontrolled  seizures, and decompensated cirrhosis.&lt;/li&gt;&#xA;    &lt;li&gt;The safety of entecavir in pregnancy is not known and IFN therapy is contraindicated.&lt;/li&gt;&#xA;&lt;/ul&gt;" />
    </Field>
  </Section>
  <Section SecID="432" OrdBy="900" Name="Qualifying Statements">
    <Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;This document presents official recommendations of the American Association for the Study of Liver Diseases (AASLD) on the treatment of chronic hepatitis B (CHB) virus (HBV) infection in adults and children. Unlike previous AASLD practice guidelines, this guideline was developed in compliance with the Institute of Medicine standards for trustworthy practice guidelines and uses the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. Multiple systematic reviews of the literature were conducted to support the recommendations in this practice guideline. An enhanced understanding of this guideline will be obtained by reading the applicable portions of the systematic reviews. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;This guideline focuses on using antiviral therapy in chronic HBV infection and does not address other related and important issues, such as screening, prevention, and surveillance. For broader issues related to diagnosis, surveillance, and prevention as well as treatment in special populations (e.g., liver transplant recipients) that are not addressed by this guideline, the previous AASLD guideline and recent World Health Organization (WHO) guideline are excellent additional resources. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
  </Section>
  <Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline">
    <Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories">
    <Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many">
      <FieldValue Value="Living with Illness" />
      <FieldValue Value="Staying Healthy" />
    </Field>
    <Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many">
      <FieldValue Value="Effectiveness" />
      <FieldValue Value="Patient-centeredness" />
      <FieldValue Value="Safety" />
    </Field>
  </Section>
  <Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability">
    <Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016 Jan;63(1):261-83. [132 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26566064&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
    <Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text">
      <FieldValue Value="2016 Jan" />
    </Field>
    <Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p">
      <FieldValue Value="American Association for the Study of Liver Diseases - Nonprofit Research Organization" />
    </Field>
    <Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The funding for the development of this Practice Guideline was provided by the American Association for the Study of Liver Diseases.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Practice Guidelines Committee&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Authors&lt;/em&gt;: Norah A. Terrault, University of California San Francisco, San Francisco, CA; Natalie H. Bzowej, Ochsner Medical Center, New Orleans, LA; Kyong-Mi Chang, Corporal Michael J. Crescenz VA Medical Center &amp;amp; University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Jessica P. Hwang, The University of Texas MD Anderson Cancer Center, Houston, TX; Maureen M. Jonas, Boston Children's Hospital, Harvard Medical School, Boston, MA; M. Hassan Murad, Mayo Clinic, Rochester, MN&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Committee Members&lt;/em&gt;: Raphael B. Merriman, MD, FACP, FRCPI (&lt;em&gt;Chair&lt;/em&gt;); Tram T. Tran, MD (&lt;em&gt;Vice-Chair&lt;/em&gt;); Michael W. Fried, MD, FAASLD (&lt;em&gt;Board Liaison&lt;/em&gt;); Jawad Ahmad, MD, FAASLD, Joseph Ahn, MD; Fredric Gordon, MD, FAASLD; Julie Heimbach, MD; Simon P. Horslen, MD; Christine Hsu, MD; Fasiha Kanwal, MD, MSHS; Michael D. Leise, MD; Marlyn J. Mayo, MD, FAASLD; Jacqueline G. O'Leary, MD; Alexander Monto, MD; Michael L. Schilsky, MD, FAASLD; Amit Singal, MD; R. Todd Stravitz, MD; Jayant A. Talwalkar, MD, MPH; Helen S. Te, MD, FAASLD; Michael Volk, MD; Helen S. Yee, PharmD&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Potential Conflict of Interest&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Dr. Jonas consults and received grants from Gilead. She received grants from Bristol-Myers Squibb and Roche. Dr. Chang advises Genentech, Alnylam, and Arbutus. Dr. Terrault consults for Bristol-Myers Squibb and received grants from Gilead. Dr. Bzowej received grants from Gilead, Synageva, and Ocera.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of this guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This updates a previous version: Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009 Sep;50(3):661-2. [304 references]&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline meets NGC's 2013 (revised) inclusion criteria.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Available from the &lt;a href=&quot;http://onlinelibrary.wiley.com/doi/10.1002/hep.28156/pdf&quot; title=&quot;Hepatology Web site&quot;&gt;Hepatology Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Lok AS, McMahon BJ, Brown RS Jr, Wong JB, Ahmed AT, Farah W, Almasri J, Alahdab F, Benkhadra K, Mouchli MA, Singh S, Mohamed EA, Abu Dabrh AM, Prokop LJ, Wang Z, Murad MH, Mohammed K. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology. 2016 Jan;63(1):284-306. Available from the &lt;a href=&quot;http://onlinelibrary.wiley.com/doi/10.1002/hep.28280/epdf&quot; title=&quot;Hepatology Web site&quot;&gt;Hepatology Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Jonas MM, Lok AS, McMahon BJ, Brown RS Jr, Wong JB, Ahmed AT, Farah W, Mouchli MA, Singh S, Prokop LJ, Murad MH, Mohammed K. Antiviral therapy in management of chronic hepatitis B viral infection in children: a systematic review and meta-analysis. Hepatology. 2016 Jan;63(1):307-18. Available from the &lt;a href=&quot;http://onlinelibrary.wiley.com/doi/10.1002/hep.28278/epdf&quot; title=&quot;Hepatology Web site&quot;&gt;Hepatology Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Brown RS Jr, McMahon BJ, Lok AS, Wong JB, Ahmed AT, Mouchli MA, Wang Z, Prokop LJ, Murad MH, Mohammed K. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis. Hepatology. 2016 Jan;63(1):319-33. Available from the &lt;a href=&quot;http://onlinelibrary.wiley.com/doi/10.1002/hep.28302/epdf&quot; title=&quot;Hepatology Web site&quot;&gt;Hepatology Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI on May 9, 2003. The information was verified by the guideline developer as of June 12, 2003. The summary was updated by ECRI on July 27, 2004. The updated information was verified by the guideline developer as of August 25, 2004. This summary was updated by ECRI Institute on June 12, 2007. The updated information was verified by the guideline developer on August 22, 2007. This summary was updated by ECRI Institute on February 26, 2010. The updated information was verified by the guideline developer on March 24, 2010. This summary was updated again by ECRI Institute on May 3, 2016.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the American Association for the Study of Liver Diseases' copyright restrictions.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="99999" OrdBy="99999" Name="Disclaimer">
    <Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text">
      <FieldValue Value="&lt;p&gt;The National Guideline Clearinghouseâ¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the &lt;a href=&quot;/help-and-about/summaries/inclusion-criteria&quot;&gt;NGC Inclusion Criteria&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" />
    </Field>
  </Section>
</Version>